摘要
Abstract
Objective To observe the clinical efficacy and safety of programmed death protein-1 inhibitor in the treatment of advanced non-small cell lung cancer.Methods A total of 60 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from January 2020 to May 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 30 cases in each group.The control group was treated with conventional violet alcohol combined with cisplatin chemotherapy,and the observation group was treated with programmed death protein-1 inhibitor on the basis of the control group.The clinical efficacy,cellular immune indexes(CD3+,CD4+,CD8+),inflammatory factor levels[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 76.67%,which was higher than 46.67%in the control group(P＜0.05).After treatment,CD3+ and CD4+ in the two groups were higher than those before treatment,CD8+ was lower than that before treatment,and CD3+ and CD4+ in the observation group were higher than those in the control group,CD8+ was lower than that in the control group(P＜0.05).After treatment,the levels of IL-6 and TNF-α in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusion Programmed death protein-1 inhibitor is effective in the treatment of advanced non-small cell lung cancer,which can improve the levels of cellular immune factors and inflammatory factors without increasing the risk of adverse reactions..关键词
程序性死亡蛋白-1抑制剂/晚期非小细胞肺癌/免疫功能/炎症因子Key words
Programmed death protein-1 inhibitors/Advanced non-small cell lung cancer/Immune function/Inflammatory factors分类
医药卫生
